Previous Article | Next Article ![]()
Journal of Virology, September 2001, p. 8259-8267, Vol. 75, No. 17
Laboratory of Infectious Diseases, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, Maryland 20892,1 and
Virology Division, United States Army Medical Research
Institute of Infectious Diseases, Fort Detrick, Maryland
217022
Received 20 March 2001/Accepted 29 May 2001
Langat virus (LGT), strain TP21, a naturally avirulent tick-borne
flavivirus, was used to construct a chimeric candidate virus vaccine
which contained LGT genes for premembrane (preM) and envelope (E)
glycoprotein and all other sequences derived from dengue type 4 virus
(DEN4). The live virus vaccine was developed to provide resistance to
the highly virulent, closely related tick-borne flaviviruses that share
protective E epitopes among themselves and with LGT. Toward that end
the chimera, initially recovered in mosquito cells, was adapted to grow
to high titer in qualified simian Vero cells. When inoculated
intraperitoneally (i.p.), the Vero cell-adapted LGT TP21/DEN4 chimera
remained completely attenuated for SCID mice. Significantly, the
chimera protected immunocompetent mice against the most virulent
tick-borne encephalitis virus (TBEV). Subsequently, rhesus monkeys were
immunized in groups of 4 with 105 or 107 PFU of
LGT strain TP21, with 105 PFU of DEN4, or with
103, 105, or 107 PFU of the
chimera. Each of the monkeys inoculated with DEN4 or LGT TP21 became
viremic, and the duration of viremia ranged from 1 to 5 days. In
contrast, viremia was detected in only 1 of 12 monkeys inoculated with
the LGT TP21/DEN4 chimera; in this instance the level of viremia was at
the limit of detection. All monkeys immunized with the chimera or LGT
TP21 virus developed a moderate to high level of neutralizing
antibodies against LGT TP21 as well as TBEV and were completely
protected against subsequent LGT TP21 challenge, whereas monkeys
previously immunized with DEN4 virus became viremic when challenged
with LGT TP21. These observations suggest that the chimera is
attenuated, immunogenic, and able to induce a protective immune
response. Furthermore, passive transfer of serum from monkeys immunized
with chimera conferred significant protection to mice subsequently
challenged with 100 i.p. 50% lethal doses of the highly virulent
TBEV. The issue of transmissibility of the chimera by mosquitoes was
addressed by inoculating a nonhematophagous mosquito,
Toxorhynchites splendens, intrathoracically with the
chimera or its DEN4 or LGT parent. Neither the LGT TP21/DEN4 vaccine
candidate nor the wild-type LGT TP21 virus was able to infect this
mosquito species, which is highly permissive for dengue viruses.
Certain properties of the chimera, notably its attenuation for monkeys,
its immunogenicity, and its failure to infect a highly permissive
mosquito host, make it a promising vaccine candidate for use in
immunization against severe disease caused by many tick-borne flaviviruses.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.17.8259-8267.2001
Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus
Chimera, a Candidate Live Attenuated Vaccine for Protection against
Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex:
Evaluation in Rhesus Monkeys and in Mosquitoes
*
Corresponding author. Mailing address: Building 7, Room
236, NIAID, NIH, 7 Center Dr., MSC 0740, Bethesda, MD 20892. Phone: (301) 402-7754. Fax: (301) 496-8312. E-mail:
apletnev{at}niaid.nih.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»